Will Israel's Teva's new celiac medication be the best thing since sliced bread?
Israeli giant Teva announced positive results in an ongoing study of a new antibody, that protects sufferers of the disease from harm triggered by gluten
Teva Pharmaceuticals announced that its experimental treatment for celiac disease, called TEV 408, is showing promising results in a recent trial. Celiac disease, an autoimmune disorder affecting around one in every hundred people, damages the small intestine when sufferers consume gluten. Traditionally, the only treatment for this condition has been a strict gluten-free diet.
Teva's antibody, TEV 408, was administered to 50 gluten-free adults with celiac disease, who then underwent a six-week gluten challenge. The trial revealed a statistically significant and clinically meaningful prevention of gluten-induced damage after eight weeks. The drug was well-tolerated, with no safety concerns reported. Teva CEO Richard Francis stated that the company has no plans to develop the drug in partnership.
Analysts were intrigued by the difference in Teva's approach compared to competitors, who often use higher doses of gluten in trials to test their drugs' effectiveness. Teva intends to provide more gluten to participants in subsequent phases of the study to provide sufficient data for the FDA's approval process.
Written by urgent.news from Haaretz's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
